# Hospital-funded protected time for clinician-scientists, repaid by trial revenue

Source: https://onco.cc/ideas/idea-fund-protected-time-physician-scientists/  
OnCo record `idea-fund-protected-time-physician-scientists` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Doctors who could turn discoveries into trials are buried in clinical work. Hospitals would guarantee them research time and recover the cost from the trials and grants they bring in.

## Summary

Cancer hospitals create a protected-time scheme (for example 40% for five years) for clinician-scientists leading translational projects, funded from a revolving pool seeded by philanthropy and repaid from the indirect costs of grants and per-patient trial income those clinicians generate. Selection is by translational plan and mentorship, not by publication record. Clinician-scientists are the people who take a lab finding into a phase 1 protocol, yet their numbers are falling in most countries because clinical productivity pays and research time is the first thing cut.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Clinicians with guaranteed protected time initiate at least twice as many investigator-led trials and translational grants per head as matched colleagues without protected time, and the scheme becomes cost-neutral to the hospital within five years through recovered indirect costs and trial income.
- Rationale: NIH's physician-scientist workforce report documents the decline; where protected time has been funded (Howard Hughes, Burroughs Wellcome career awards, UK academic clinical lecturer posts) retention and output are markedly higher. Trial income is a real revenue line at cancer centres and can be earmarked.
- Proposed test: Two cancer centres run the scheme for five years with financial tracking and compare trial initiations and grant income of protected clinicians with a matched internal control group.
- Maturity: speculative
- Actor: clinic

## Sources

- Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008): https://doi.org/10.1038/453840a

## Connected records

- ideas: [Funded research pathways for surgeon-scientists and radiation oncologist-scientists](https://onco.cc/ideas/idea-fund-surgeon-scientist-pathway/), [Two-year translational fellowships that pay scientists to develop their own discovery](https://onco.cc/ideas/idea-fund-translational-fellowships/)
- bottlenecks: [Not enough oncologists, nurses, pathologists, physicists](https://onco.cc/bottlenecks/b-workforce/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- key papers: [Translational research: crossing the valley of death](https://onco.cc/key-papers/paper-butler-nature/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-protected-time-physician-scientists.json